ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1580858
Exploration of the clinical prognostic model of BRCA based on PCAT7
Provisionally accepted- 1Wuming Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi Zhuang Region, China
- 2YuanDong International Academy Of Life Sciences, HongKong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: Breast cancer (BRCA) is the most common cancer in women. Overexpression of long non-coding RNA Prostate cancer-associated transcript 7 (PCAT7) in BRCA was correlated with an unfavorable prognosis. Consequently, investigating the function and prognostic significance of PCAT7 in BRCA has become imperative.Methods: This study used BRCA data from the Cancer Genome Atlas (TCGA) as a training cohort to evaluate the prognostic potential of PCAT7. In addition, luminal A, luminal B, HER2, and basal like triple-negative breast cancer samples were collected clinically to verify the expression of PCAT7. Meanwhile, differentially expressed genes (DEGs) related to PCAT7 were identified. Subsequently, weighted gene co-expression network analysis (WGCNA) was used to identify abnormal regulatory modules of PCAT7 co-expressed genes in BRCA. Furthermore, we used enrichment analysis to evaluate the distribution patterns of genes. We constructed a clinical indicator scoring model based on PCAT7 based prognosis-related genes, followed by correlation analyses to study the relationship between clinical indicators based on PCAT7 expression and immune cell infiltration, immune checkpoint-related genes, and tertiary lymphoid structure marker genes. Pivot analysis based on a hypergeometric approach was used to identify lncRNAs, TFs and RBPs that regulate the set of prognosis-related genes to explore drug targets.Results: The results showed that PCAT7 was significantly high expression in BRCA, and patients with high expression of PCAT7 had poor prognosis. IHC further confirmed that PCAT7 was significantly overexpressed in BRCA samples of different subtypes, suggesting that PCAT7 has diagnostic potential in BRCA. Meanwhile, a total of 28,892 DEGs and 954 DEmiRNAs were continuously upregulated or downregulated. The most relevant module genes associated with PCAT7 are significantly enriched in immune and cancer-related pathways. PCAT7-based models and model genes were significantly associated with multiple immune checkpoint-related genes and tertiary lymphoid structure marker genes. In addition, PCAT7 is associated with the inhibition of immune cell infiltration.Conclusion: We found that the clinical score of PCAT7 is significantly correlated with the prognosis of BRCA patients, suggesting that PCAT7 is a useful biomarker.
Keywords: PCAT7, BRCA, WGCNA, immune cells, PCAT7 clinical model
Received: 21 Feb 2025; Accepted: 09 Jul 2025.
Copyright: © 2025 Zhang, Xiang, Chen, Ma, Wang, Li, Chen, Huang, Li, Wu, Mo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Steven Mo, YuanDong International Academy Of Life Sciences, HongKong, China
Dequan Li, YuanDong International Academy Of Life Sciences, HongKong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.